View Future GrowthDhansa Labs 過去の業績過去 基準チェック /36Dhansa Labsの収益は年間平均-10.8%の割合で減少していますが、 Chemicals業界の収益は年間 増加しています。収益は年間5.8% 10.4%割合で 増加しています。 Dhansa Labsの自己資本利益率は5.6%であり、純利益率は3.9%です。主要情報-10.82%収益成長率-61.05%EPS成長率Chemicals 業界の成長17.68%収益成長率10.43%株主資本利益率5.59%ネット・マージン3.87%前回の決算情報31 Mar 2026最近の業績更新Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.お知らせ • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026お知らせ • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).すべての更新を表示Recent updatesReported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.お知らせ • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).分析記事 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).分析記事 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...お知らせ • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.お知らせ • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.分析記事 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).お知らせ • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.お知らせ • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144ABoard Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.収支内訳Dhansa Labs の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。収益と収入の歴史NSEI:DHANSA 収益、費用、利益 ( )INR Millions日付収益収益G+A経費研究開発費31 Mar 261,4285512031 Dec 251,3785020030 Sep 251,3284429030 Jun 251,3284629031 Mar 251,3294829031 Dec 241,3144728030 Sep 241,2984727030 Jun 241,2596227031 Mar 241,2197728031 Mar 231,0755236031 Mar 228493630031 Mar 2182110328031 Mar 206702520質の高い収益: DHANSA 非現金収入 のレベルが高いです。利益率の向上: DHANSAの現在の純利益率 (3.9%)は、昨年(3.6%)よりも高くなっています。フリー・キャッシュフローと収益の比較過去の収益成長分析収益動向: DHANSAの収益は過去 5 年間で年間10.8%減少しました。成長の加速: DHANSAの過去 1 年間の収益成長率 ( 15.5% ) は、5 年間の平均 ( 年間-10.8%を上回っています。収益対業界: DHANSAの過去 1 年間の収益成長率 ( 15.5% ) はChemicals業界11.9%を上回りました。株主資本利益率高いROE: DHANSAの 自己資本利益率 ( 5.6% ) は 低い とみなされます。総資産利益率使用総資本利益率過去の好業績企業の発掘7D1Y7D1Y7D1YMaterials 、過去の業績が好調な企業。View Financial Health企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/06/02 11:38終値2026/05/29 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Dhansa Labs Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.
お知らせ • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026
お知らせ • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025
Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).
Reported Earnings • Jun 01Full year 2026 earnings released: EPS: ₹2.21 (vs ₹2.06 in FY 2025)Full year 2026 results: EPS: ₹2.21 (up from ₹2.06 in FY 2025). Revenue: ₹1.43b (up 7.5% from FY 2025). Net income: ₹55.2m (up 16% from FY 2025). Profit margin: 3.9% (up from 3.6% in FY 2025). The increase in margin was driven by higher revenue.
お知らせ • May 23Ambey Laboratories Limited to Report Second Half, 2026 Results on May 29, 2026Ambey Laboratories Limited announced that they will report second half, 2026 results on May 29, 2026
Valuation Update With 7 Day Price Move • Apr 24Investor sentiment improves as stock rises 37%After last week's 37% share price gain to ₹37.05, the stock trades at a trailing P/E ratio of 20.8x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 2.2% over the past year.
Valuation Update With 7 Day Price Move • Apr 07Investor sentiment improves as stock rises 16%After last week's 16% share price gain to ₹21.90, the stock trades at a trailing P/E ratio of 12.3x. Average trailing P/E is 20x in the Chemicals industry in India. Total loss to shareholders of 49% over the past year.
Valuation Update With 7 Day Price Move • Feb 26Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹23.00, the stock trades at a trailing P/E ratio of 12.9x. Average trailing P/E is 22x in the Chemicals industry in India. Total loss to shareholders of 55% over the past year.
New Risk • Jan 12New major risk - Market cap sizeThe company's market capitalization is less than US$10m. Market cap: ₹899.3m (US$9.97m) This is considered a major risk. Companies with a small market capitalization are most likely businesses that have not yet released a product to market or are simply a very small company without a wide reach. Either way, risk is elevated with these companies because there is a chance the product may not come to fruition or the company's addressable market or demand may not be as large as expected. In addition, if the company's size is the main factor, it is less likely to have many investors and analysts following it and scrutinizing its performance and outlook. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Share price has been highly volatile over the past 3 months (8.9% average weekly change). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Market cap is less than US$10m (₹899.3m market cap, or US$9.97m).
分析記事 • Jan 08Ambey Laboratories (NSE:AMBEY) Could Be Struggling To Allocate CapitalIf you're not sure where to start when looking for the next multi-bagger, there are a few key trends you should keep an...
Valuation Update With 7 Day Price Move • Dec 29Investor sentiment improves as stock rises 19%After last week's 19% share price gain to ₹44.35, the stock trades at a trailing P/E ratio of 24.9x. Average trailing P/E is 23x in the Chemicals industry in India. Total loss to shareholders of 30% over the past year.
New Risk • Dec 23New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (8.0% average weekly change). Market cap is less than US$100m (₹1.08b market cap, or US$12.1m).
New Risk • Nov 24New major risk - Revenue and earnings growthEarnings have declined by 13% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Interest payments are not well covered by earnings (3.0x net interest cover). Earnings have declined by 13% per year over the past 5 years. High level of non-cash earnings (60% accrual ratio). Minor Risk Market cap is less than US$100m (₹1.05b market cap, or US$11.7m).
分析記事 • Nov 15There Is A Reason Ambey Laboratories Limited's (NSE:AMBEY) Price Is UndemandingWith a price-to-earnings (or "P/E") ratio of 22.6x Ambey Laboratories Limited ( NSE:AMBEY ) may be sending bullish...
お知らせ • Nov 14Ambey Laboratories Limited to Report First Half, 2026 Results on Nov 14, 2025Ambey Laboratories Limited announced that they will report first half, 2026 results on Nov 14, 2025
Board Change • Oct 01High number of new and inexperienced directorsThere are 5 new directors who have joined the board in the last 3 years. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. Independent Non-Executive Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. The following issues are considered to be risks according to the Simply Wall St Risk Model: Lack of board continuity. Lack of experienced directors.
Reported Earnings • Sep 08Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.0% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
お知らせ • Sep 04Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2025, at 15:00 Indian Standard Time.
Valuation Update With 7 Day Price Move • Jul 21Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹44.75, the stock trades at a trailing P/E ratio of 23.3x. Average trailing P/E is 30x in the Chemicals industry in India. Total loss to shareholders of 45% over the past year.
分析記事 • Jul 19Ambey Laboratories Limited's (NSE:AMBEY) Business And Shares Still Trailing The MarketAmbey Laboratories Limited's ( NSE:AMBEY ) price-to-earnings (or "P/E") ratio of 22x might make it look like a buy...
New Risk • Jun 09New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (60% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.04b market cap, or US$12.1m).
Reported Earnings • Jun 05Full year 2025 earnings released: EPS: ₹2.06 (vs ₹4.25 in FY 2024)Full year 2025 results: EPS: ₹2.06 (down from ₹4.25 in FY 2024). Revenue: ₹1.33b (up 9.2% from FY 2024). Net income: ₹47.8m (down 38% from FY 2024). Profit margin: 3.6% (down from 6.3% in FY 2024). The decrease in margin was driven by higher expenses.
New Risk • Jun 02New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended September 2024. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (10% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Latest financial reports are more than 6 months old (reported September 2024 fiscal period end). Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹1.01b market cap, or US$11.8m).
New Risk • May 19New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.0% average weekly change). High level of non-cash earnings (76% accrual ratio). Minor Risks Profit margins are more than 30% lower than last year (3.6% net profit margin). Market cap is less than US$100m (₹948.0m market cap, or US$11.1m).
Valuation Update With 7 Day Price Move • May 19Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹45.55, the stock trades at a trailing P/E ratio of 24.1x. Average trailing P/E is 26x in the Chemicals industry in India.
Reported Earnings • Nov 18First half 2025 earnings releasedFirst half 2025 results: EPS: ₹0.16. Net income: ₹29.7m (up ₹29.7m from 1H 2024).
New Risk • Sep 15New major risk - Financial positionThe company's debt is not well covered by operating cash flow. Currently running at an operating cash loss. This is considered a major risk. If the company's operating cash flows are too small relative to the size of their debt, it increases their balance sheet risk. The company has less cash from operations to cover its expenses from servicing large debt and it increases the risk of liquidity issues. It also extends the time it would take for the company to pay back the debt in full, meaning it may not be able to easily pay it all off in a distress scenario. Currently, the following risks have been identified for the company: Major Risks Debt is not well covered by operating cash flow (currently running at an operating cash loss). High level of non-cash earnings (54% accrual ratio). Minor Risks Share price has been volatile over the past 3 months (9.0% average weekly change). Market cap is less than US$100m (₹1.77b market cap, or US$21.1m).
お知らせ • Sep 13Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024Ambey Laboratories Limited, Annual General Meeting, Sep 30, 2024, at 13:00 Indian Standard Time.
New Risk • Aug 23New minor risk - Financial data availabilityThe company's latest financial reports are more than 6 months old. Last reported fiscal period ended March 2023. This is considered a minor risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. Currently, the following risks have been identified for the company: Minor Risks High level of debt (53% net debt to equity). Latest financial reports are more than 6 months old (reported March 2023 fiscal period end). Market cap is less than US$100m (₹1.96b market cap, or US$23.4m).
Valuation Update With 7 Day Price Move • Aug 22Investor sentiment improves as stock rises 18%After last week's 18% share price gain to ₹78.75, the stock trades at a trailing P/E ratio of 43x. Average trailing P/E is 35x in the Chemicals industry in India.
Valuation Update With 7 Day Price Move • Aug 01Investor sentiment deteriorates as stock falls 18%After last week's 18% share price decline to ₹69.20, the stock trades at a trailing P/E ratio of 37.8x. Average trailing P/E is 35x in the Chemicals industry in India.
Buy Or Sell Opportunity • Jul 23Now 21% undervaluedThe stock has been flat over the last 90 days, currently trading at ₹76.85. The fair value is estimated to be ₹97.52, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 26% over the last year. Earnings per share has declined by 64%.
お知らせ • Jul 11Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million.Ambey Laboratories Limited has completed an IPO in the amount of INR 446.76 million. Security Name: Equity Shares Security Type: Common Stock Securities Offered: 330,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,868,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 1,252,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 936,000 Price\Range: INR 68 Security Name: Equity Shares Security Type: Common Stock Securities Offered: 2,184,000 Price\Range: INR 68 Transaction Features: Regulation S; Rule 144A
Board Change • Jul 11Less than half of directors are independentThere are 5 new directors who have joined the board in the last 3 years. Of these new board members, 2 were independent directors. The company's board is composed of: 5 new directors. No experienced directors. No highly experienced directors. 2 independent directors (3 non-independent directors). Independent Director Abdul Quadir is the most experienced director on the board, commencing their role in 2022. Independent Director Roni Soni was the last independent director to join the board, commencing their role in 2023. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Lack of board continuity. Lack of experienced directors.